Predictors of consent to pharmacogenomics testing in the IDEAL study

Alison B. Jazwinski, Paul J. Clark, Alexander J. Thompson, Stuart C. Gordon, Eric J. Lawitz, Stephanie Noviello, Clifford A. Brass, Lisa D. Pedicone, Janice K. Albrecht, Mark Sulkowski, Andrew J. Muir

Research output: Contribution to journalArticle

Abstract

INTRODUCTION: Pharmacogenomic testing is important in developing individualized therapeutic approaches. In the phase 3 IDEAL (Individualized Dosing to Assess Optimal Pegylated Interferon Therapy) clinical trial, a subset of patients receiving peginterferon and ribavirin for treatment of chronic hepatitis C agreed to provide blood samples for genetic testing. Genome-wide association studies subsequently identified associations between IL28B polymorphism and sustained virologic response, and ITPA polymorphism and ribavirin-associated anemia. OBJECTIVE: To characterize the groups of patients who accepted or declined pharmacogenomic testing in the IDEAL study. METHODS: Clinical and demographic factors and treatment outcomes were compared at all sites that had approved pharmacogenomic testing. Differences between patients who consented to and declined pharmacogenomic testing were analyzed using Student's t-test and χ2-test. RESULTS: In total, 109 of 118 sites participated in the pharmacogenomic substudy, and 1674 of 2949 (57%) patients enrolled at these sites consented to pharmacogenomic testing. More patients treated in academic medical centers than in community centers (60 vs. 52%, P

Original languageEnglish (US)
Pages (from-to)619-623
Number of pages5
JournalPharmacogenetics and Genomics
Volume23
Issue number11
DOIs
StatePublished - Nov 2013

Fingerprint

Ribavirin
Genome-Wide Association Study
Pharmacogenetics
Genetic Testing
Chronic Hepatitis C
Interferons
Anemia
Therapeutics
Demography
Pharmacogenomic Testing
Clinical Trials
Students
Sustained Virologic Response

Keywords

  • Hepatitis C
  • Peginterferon
  • Pharmacogenomics
  • Ribavirin

ASJC Scopus subject areas

  • Genetics
  • Molecular Biology
  • Molecular Medicine
  • Genetics(clinical)

Cite this

Jazwinski, A. B., Clark, P. J., Thompson, A. J., Gordon, S. C., Lawitz, E. J., Noviello, S., ... Muir, A. J. (2013). Predictors of consent to pharmacogenomics testing in the IDEAL study. Pharmacogenetics and Genomics, 23(11), 619-623. https://doi.org/10.1097/FPC.0000000000000002

Predictors of consent to pharmacogenomics testing in the IDEAL study. / Jazwinski, Alison B.; Clark, Paul J.; Thompson, Alexander J.; Gordon, Stuart C.; Lawitz, Eric J.; Noviello, Stephanie; Brass, Clifford A.; Pedicone, Lisa D.; Albrecht, Janice K.; Sulkowski, Mark; Muir, Andrew J.

In: Pharmacogenetics and Genomics, Vol. 23, No. 11, 11.2013, p. 619-623.

Research output: Contribution to journalArticle

Jazwinski, AB, Clark, PJ, Thompson, AJ, Gordon, SC, Lawitz, EJ, Noviello, S, Brass, CA, Pedicone, LD, Albrecht, JK, Sulkowski, M & Muir, AJ 2013, 'Predictors of consent to pharmacogenomics testing in the IDEAL study', Pharmacogenetics and Genomics, vol. 23, no. 11, pp. 619-623. https://doi.org/10.1097/FPC.0000000000000002
Jazwinski AB, Clark PJ, Thompson AJ, Gordon SC, Lawitz EJ, Noviello S et al. Predictors of consent to pharmacogenomics testing in the IDEAL study. Pharmacogenetics and Genomics. 2013 Nov;23(11):619-623. https://doi.org/10.1097/FPC.0000000000000002
Jazwinski, Alison B. ; Clark, Paul J. ; Thompson, Alexander J. ; Gordon, Stuart C. ; Lawitz, Eric J. ; Noviello, Stephanie ; Brass, Clifford A. ; Pedicone, Lisa D. ; Albrecht, Janice K. ; Sulkowski, Mark ; Muir, Andrew J. / Predictors of consent to pharmacogenomics testing in the IDEAL study. In: Pharmacogenetics and Genomics. 2013 ; Vol. 23, No. 11. pp. 619-623.
@article{5874d03a4ba54c5aaf073a1bcf34d502,
title = "Predictors of consent to pharmacogenomics testing in the IDEAL study",
abstract = "INTRODUCTION: Pharmacogenomic testing is important in developing individualized therapeutic approaches. In the phase 3 IDEAL (Individualized Dosing to Assess Optimal Pegylated Interferon Therapy) clinical trial, a subset of patients receiving peginterferon and ribavirin for treatment of chronic hepatitis C agreed to provide blood samples for genetic testing. Genome-wide association studies subsequently identified associations between IL28B polymorphism and sustained virologic response, and ITPA polymorphism and ribavirin-associated anemia. OBJECTIVE: To characterize the groups of patients who accepted or declined pharmacogenomic testing in the IDEAL study. METHODS: Clinical and demographic factors and treatment outcomes were compared at all sites that had approved pharmacogenomic testing. Differences between patients who consented to and declined pharmacogenomic testing were analyzed using Student's t-test and χ2-test. RESULTS: In total, 109 of 118 sites participated in the pharmacogenomic substudy, and 1674 of 2949 (57{\%}) patients enrolled at these sites consented to pharmacogenomic testing. More patients treated in academic medical centers than in community centers (60 vs. 52{\%}, P",
keywords = "Hepatitis C, Peginterferon, Pharmacogenomics, Ribavirin",
author = "Jazwinski, {Alison B.} and Clark, {Paul J.} and Thompson, {Alexander J.} and Gordon, {Stuart C.} and Lawitz, {Eric J.} and Stephanie Noviello and Brass, {Clifford A.} and Pedicone, {Lisa D.} and Albrecht, {Janice K.} and Mark Sulkowski and Muir, {Andrew J.}",
year = "2013",
month = "11",
doi = "10.1097/FPC.0000000000000002",
language = "English (US)",
volume = "23",
pages = "619--623",
journal = "Pharmacogenetics and Genomics",
issn = "1744-6872",
publisher = "Lippincott Williams and Wilkins",
number = "11",

}

TY - JOUR

T1 - Predictors of consent to pharmacogenomics testing in the IDEAL study

AU - Jazwinski, Alison B.

AU - Clark, Paul J.

AU - Thompson, Alexander J.

AU - Gordon, Stuart C.

AU - Lawitz, Eric J.

AU - Noviello, Stephanie

AU - Brass, Clifford A.

AU - Pedicone, Lisa D.

AU - Albrecht, Janice K.

AU - Sulkowski, Mark

AU - Muir, Andrew J.

PY - 2013/11

Y1 - 2013/11

N2 - INTRODUCTION: Pharmacogenomic testing is important in developing individualized therapeutic approaches. In the phase 3 IDEAL (Individualized Dosing to Assess Optimal Pegylated Interferon Therapy) clinical trial, a subset of patients receiving peginterferon and ribavirin for treatment of chronic hepatitis C agreed to provide blood samples for genetic testing. Genome-wide association studies subsequently identified associations between IL28B polymorphism and sustained virologic response, and ITPA polymorphism and ribavirin-associated anemia. OBJECTIVE: To characterize the groups of patients who accepted or declined pharmacogenomic testing in the IDEAL study. METHODS: Clinical and demographic factors and treatment outcomes were compared at all sites that had approved pharmacogenomic testing. Differences between patients who consented to and declined pharmacogenomic testing were analyzed using Student's t-test and χ2-test. RESULTS: In total, 109 of 118 sites participated in the pharmacogenomic substudy, and 1674 of 2949 (57%) patients enrolled at these sites consented to pharmacogenomic testing. More patients treated in academic medical centers than in community centers (60 vs. 52%, P

AB - INTRODUCTION: Pharmacogenomic testing is important in developing individualized therapeutic approaches. In the phase 3 IDEAL (Individualized Dosing to Assess Optimal Pegylated Interferon Therapy) clinical trial, a subset of patients receiving peginterferon and ribavirin for treatment of chronic hepatitis C agreed to provide blood samples for genetic testing. Genome-wide association studies subsequently identified associations between IL28B polymorphism and sustained virologic response, and ITPA polymorphism and ribavirin-associated anemia. OBJECTIVE: To characterize the groups of patients who accepted or declined pharmacogenomic testing in the IDEAL study. METHODS: Clinical and demographic factors and treatment outcomes were compared at all sites that had approved pharmacogenomic testing. Differences between patients who consented to and declined pharmacogenomic testing were analyzed using Student's t-test and χ2-test. RESULTS: In total, 109 of 118 sites participated in the pharmacogenomic substudy, and 1674 of 2949 (57%) patients enrolled at these sites consented to pharmacogenomic testing. More patients treated in academic medical centers than in community centers (60 vs. 52%, P

KW - Hepatitis C

KW - Peginterferon

KW - Pharmacogenomics

KW - Ribavirin

UR - http://www.scopus.com/inward/record.url?scp=84886587836&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84886587836&partnerID=8YFLogxK

U2 - 10.1097/FPC.0000000000000002

DO - 10.1097/FPC.0000000000000002

M3 - Article

C2 - 24061202

AN - SCOPUS:84886587836

VL - 23

SP - 619

EP - 623

JO - Pharmacogenetics and Genomics

JF - Pharmacogenetics and Genomics

SN - 1744-6872

IS - 11

ER -